Heart Failure pp 279-288 | Cite as

Types of Circulatory Support Devices

  • Joseph G. RogersEmail author
Part of the Cardiovascular Medicine book series (CVM)


There are many conceptual ways to consider the devices intended to support the circulation: the indication for implantation, type of device, the ventricles supported, the anticipated duration of support and the acuity of patient need. For example, devices used to support a patient in cardiogenic shock following an acute myocardial infarction are different from those used to treat a patient in chronic advanced heart failure who will live permanently on a device. In the remainder of this chapter, mechanical circulatory support devices will be presented as those intended for either short- or long-term support.


  1. 1.
    Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. Am J Cardiol. 2006;97:1391–8.CrossRefGoogle Scholar
  2. 2.
    Santa-Cruz RA, Cohen MG, Ohman EM. Aortic counterpulsation: a review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv. 2006;67:68–77.CrossRefGoogle Scholar
  3. 3.
    Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, Chou TM. For the investigators in the National Registry of myocardial infarction 2. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complication acute myocardial infarction: data from the National Registry of myocardial infarction 2. Am Heart J. 2001;141:933–9.CrossRefGoogle Scholar
  4. 4.
    Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, Balestrini C, Wharton T, Esenta P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Grines L, O’Neill WW, Grines C. A prospective, randomized evaluation of prophylactic intra-aortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol. 1997;29:1459–67.CrossRefGoogle Scholar
  5. 5.
    Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287–96.CrossRefGoogle Scholar
  6. 6.
    Estep JD, Cordero-Reyes AM, Bhimaraj A, Trachtenberg B, Khalil N, Loebe M, Bruckner B, Orrego CM, Bismuth J, Kleiman NS, Torre-Amione G. Percutaneous placement of an intra-aortic balloon pump in the left axillary/subclavian position provides safe, ambulatory long-term support as bridge to heart transplantation. JACC Heart Fail. 2013;1:382–8.CrossRefGoogle Scholar
  7. 7.
    Lima B, Kale P, Gonzalez-Stawinski GV, Kuiper JJ, Carey S, Hall S. Effectiveness and safety of the Impella 5.0 as a bridge to transplantation or durable left ventricular assist device. Am J Cardiol. 2016;117:1622–8.CrossRefGoogle Scholar
  8. 8.
    O’Neill WW, Kleiman BS, Moses J, et al. A prospective randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention. The PROTECT II study. Circulation. 2012;126:1717–27.CrossRefGoogle Scholar
  9. 9.
    Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJS, Vis MM, Wykrzkowska JJ, Koch KT, Baan J, de Winter RJ, Piek JJ, Lagrand WK, de Mol B, Tijssen JGP, Henriques JPS. Impella CP versus intra-aotic balloon pump in acute myocardial infarction complicated by cardiogenic shock: The IMPRESS trial. J Am Coll Cardiol. 2016; ePub ahead of print.Google Scholar
  10. 10.
    Ouweneel DM, Eriksen E, Seyfarth M, Henriques JPS. Impella versus intra-aortic balloon pump for the treatment of cardiogenic shock: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2016; ePub ahead of print.Google Scholar
  11. 11.
    Griffith BP, Anderson MB, Samuels LE, et al. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013;145:548–54.CrossRefGoogle Scholar
  12. 12.
    Anderson MB, Goldstein J, Milano CA, Morris LD, Kormos RL, Bhama J, Kapur NK, Bansal A, Garcia J, Baker JN, Silvestry S, Holman WL, Douglas PS, O’Neill W. Benefits of a novel percutaneous ventricular assist device for the right heart: the prospective RECOVER RIGHT study of the IMPELLA RP device. J Heart Lung Transplant. 2015;34:1549–60.CrossRefGoogle Scholar
  13. 13.
    Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57:688–96.CrossRefGoogle Scholar
  14. 14.
    Allen S, Holena D, McCunn M, Kohl B, Sarani B. A review of the fundamental principles and evidence base in the use of extracorporeal membrane oxygenation (ECMO) in critically III adult patients. J Intensive Care Med. 2011;26:13–26.CrossRefGoogle Scholar
  15. 15.
    Bougouin W, Aissaoui N, Combes A, Deye N, Lamhaut L, Jost D, Maupain C, Beganton F, Bougle A, Karam N, Dumas F, Marijon E, Jouven X, Cariou A, on behalf SDEC Investigators. Post-cardiac arrest shock treated with veno-arterial extracorporeal membrane oxygenation An observational study and propensity analysis. Resuscitation. 2017;110:126–32.CrossRefGoogle Scholar
  16. 16.
    Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaroonson KD, Conte JV, Naka Y, Mancini D, Delgado RM, MacGillivray TE, Farrar DJ, Frazier OH. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefGoogle Scholar
  17. 17.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefGoogle Scholar
  18. 18.
    Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selman CH, Shah KB, Loebe M, Moazami N, Long JW, Stehlik J, Kasirijan V, Haas DC, O’Connell JB, Boyle AJ, Farrar DJ, Rogers JG. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients. J Am Coll Cardiol. 2015;66:1747–61.CrossRefGoogle Scholar
  19. 19.
    Netuka I, Sood P, Pya Y ZD, Krabatsch T, Gaargade J, Rao V, Morshuis M, Marasco S, Beyersdorf J, Damme L, Schmitto JD. Fully magnetically levitated left ventricular assist system for treating advanced heart failure. J Am Coll Cardiol. 2015;66:2579–89.CrossRefGoogle Scholar
  20. 20.
    Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC, Colombo PC, Walsh MN, Milarno CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2016; ePub ahead of print.Google Scholar
  21. 21.
    Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandam V, Anderson AS, Kormos RL, Teuteberg JJ, Levy WC, Naftel DC, Bittman RM, Pagani FD, Hathaway DR, Boyce SW, for the HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191–200.CrossRefGoogle Scholar
  22. 22.
    Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CAIntra-pericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376:451–60.CrossRefGoogle Scholar
  23. 23.
    Teuteberg JJ, Slaughter MS, Rogers JG, McGee EC, Pagani FD, Gordon R, Rame E, Acker M, Kormos RL, Salerno C, Schleeter TP, Goldstein DJ, Shin J, Starling RC, Wozniak T, Malik AS, Silvestry S, Ewald GA, Jorde UP, Naka Y, Birks E, Najarian KB, Hathaway DR, Aaronson KD, for the ADVANCE Investigators. The HVAD left ventricular assist device. Risk factors for neurological events and risk mitigation strategies. JACC Heart Fail. 2015;3:818–28.CrossRefGoogle Scholar
  24. 24.
    Fraser CD, Jaquiss R, Rosenthal DN, Humpl T, Canter CE, Blackstone EH, Naftel DC, Ichord RN, Bomgaars L, Tweddell JS, Massicotte P, Turrentine MW, Cohen GA, Devaney EJ, Pearce FB, Carberry KE, Kroslowitz R, Almond CS, for the Berlin Heart Study Investigators. Prospective trial of a pediatric ventricular assist device. N Engl J Med. 2012;367:532–41.CrossRefGoogle Scholar
  25. 25.
    Mohacsi P, Leprince P. The CARMAT total artificial heart. Eur J Cardiothorac Surg. 2014;46:933–4.CrossRefGoogle Scholar
  26. 26.
    Goerlich CE, Frazier OH, Cohn WE. Previous challenges and current progress – the use of total artificial heart in patients with end-stage heart failure. Expert Rev Cardiovasc Ther. 2016;14:1095–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of CardiologyDuke UniversityDurhamUSA

Personalised recommendations